BioCentury | Dec 2, 2016
Company News

Allergan, Chase deal

...Allergan acquired Chase for $125 million up front, plus undisclosed milestones tied to the company's CPC-201...
...to treat Alzheimer's disease. Allergan said it plans to begin a Phase III trial of CPC-201...
...Chase pairs complementary molecules with marketed AD drugs to improve the drugs' side effect profiles. CPC-201...
BioCentury | Nov 23, 2016
Company News

Allergan acquires Chase

...Washington, D.C.) for $125 million up front, plus milestones tied to the company's lead candidate, CPC-201...
...Chase pairs complementary molecules with marketed AD drugs to improve the drugs' side effect profiles. CPC-201...
BioCentury | Sep 5, 2016
Clinical News

CPC-201: Phase II data

...with AD type dementia who were being successfully treated with 10 mg/day donepezil showed that CPC-201...
...at the Alzheimer’s Association International Conference in Toronto. Chase Pharmaceuticals Corp. , Washington, D.C. Product: CPC-201...
BioCentury | May 19, 2014
Finance

Giving Chase in AD

...million series B round will give it four years of runway and get lead program CPC-201...
...Accelerator Fund also participated. EdRIP's Raphael Wisniewski and Cipla's Vikram Sudarsan joined the biotech's board. CPC-201...
...side effects will allow them to be dosed higher." In Phase I studies, he said CPC-201...
BioCentury | May 13, 2014
Financial News

Chase secures $21 million in series B

...Next quarter, the company plans to start Phase II testing of CPC-201 to treat AD. CPC-201...
Items per page:
1 - 5 of 5